✦ LIBER ✦

Incidence and clinical progression of placebo-treated amyloid-negative subjects with mild-to-moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab

✍ Scribed by Salloway, Stephen; Sperling, Reisa; Gregg, Keith; Yu, Peng; Joshi, Abhinay; Lu, Ming; Mintun, Mark; Pontecorvo, Michael; Booth, Kevin; Wyman, Bradley; Sun, Jia; Sundell, Karen; Schmidt, Mark; Margolin, Richard; Skovronsky, Daniel; Liu, Enchi; Siemers, Eric; Brashear, Robert H.

Book ID: 122485957
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 134 KB
Volume: 9
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.08.250

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation of brain atrophy with clinic

Correlation of brain atrophy with clinical progression in mild-to-moderate Alzheimer's disease: Results from the volumetric MRI substudies of two phase III trials with bapineuzumab

✍ Novak, Gerald; Einstein, Steven; Lu, Yuan; Tudor, Iulia Cristina; Gregg, Keith; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

The rate of clinical progression and bra

The rate of clinical progression and brain atrophy is greater with increasing severity of Alzheimer's disease: Results from the volumetric MRI substudies of two phase III trials with bapineuzumab

✍ Novak, Gerald; Einstein, Steven; Tudor, Iulia Cristina; Gregg, Keith; Collins, P 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB